IQVIA: Most Eligible Patients Buy On Their Own

Table of contents:

IQVIA: Most Eligible Patients Buy On Their Own
IQVIA: Most Eligible Patients Buy On Their Own

Video: IQVIA: Most Eligible Patients Buy On Their Own

Отличия серверных жестких дисков от десктопных
Video: WE ARE IQVIA 2023, February
Anonim

IQVIA: Most Eligible Patients Buy On Their Own

The incidence of respiratory diseases is growing in Russia. Drug sales are increasing, with most patients buying them at their own expense. And the norm of budgetary allocations for the provision of medicines for one patient with respiratory diseases is about 10 thousand rubles a year. In such a situation, it is only theoretically possible to talk about the use of modern therapy.

IQVIA: Most Eligible Patients Buy On Their Own
IQVIA: Most Eligible Patients Buy On Their Own

Photo: pixabay.com /

The incidence of respiratory diseases is growing in Russia. Pharmacy sales of the corresponding drugs increase annually by 7-9%, while the majority of patients are forced to purchase them at their own expense. And the norm of budgetary allocations for the provision of medicines for one patient with respiratory diseases is about 10 thousand rubles a year. In such a situation, it is only theoretically possible to talk about the use of modern therapy.

A study on the use of drugs for the treatment of bronchopulmonary diseases was presented by the International Analytical Agency IQVIA during the XXVIII National Congress on Respiratory Diseases, which was held last week in Moscow. According to IQVIA, in recent years in Russia, the use of drugs for the treatment of respiratory diseases has been increasing, among which drugs for the treatment of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) predominate, which indicates an increase in the number of patients suffering from bronchopulmonary diseases. Thus, in 2016, Russian patients needed 28.75 million packages of the corresponding drugs, which is 7.01% more than in 2015. In 2017, this number increased by another 9.64% and amounted to 31.52 million packs.

In Russia, COPD and BA are classified as socially significant diseases. These diseases occupy the third place in the overall structure of mortality, significantly reduce the duration and quality of life, and affect performance. Patients with such diseases require lifelong regular use of drugs as basic therapy and to prevent exacerbations. When determining the degree of disability, patients with BA and COPD are provided with the necessary drugs at the expense of the state budget under the program of preferential drug provision. However, the majority of patients (60%) choose to monetize their benefits and buy the necessary drugs themselves, IQVIA experts found out. And this despite the fact that the cost of a monthly course was 30-200% higher than the amounts received by patients during monetization.

More than 63% of drugs used to treat COPD and asthma are emergency drugs - short-acting beta-agonists, the study says. Moreover, according to modern clinical guidelines, the treatment of obstructive pulmonary diseases is based on combined drugs (long-acting bronchodilator and inhalation hormone). And for several years now, the pharmaceutical industry has been producing new generation drugs suitable for both basic therapy and for relief of seizures.

In addition, according to the participants of the National Congress, the success of BA and COPD therapy largely depends on the patient's compliance with the recommended dosage and the frequency of administration of the drug. However, most patients take medication incorrectly due to purely technical errors, for example, it is difficult for a person to clearly synchronize respiratory efforts with the moment of activation of the dosing device, as written in the instructions. As a result, treatment does not achieve the desired effect in three quarters of patients. New generation drugs, produced in the form of mini-inhalers with a precisely calculated amount of the drug, solve this problem as well.

“This problem is being discussed in the professional community,” said Vice-Rector of the Pacific State Medical University, Professor Yekaterina Yeleseeva. “The existing bias in the treatment of COPD and asthma needs to be corrected by replacing short-acting beta-agonists with more effective modern combined drugs and long-acting bronchodilators.”

Popular by topic